Harrison Pharmaceutical

Shanghai Harrison Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company specializing in the development and manufacturing of respiratory and cardiovascular treatments. Founded in 2003, the company is recognized as a national high-tech enterprise, with a core focus on inhalation drug delivery technologies, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nasal sprays. Its commercial portfolio features essential respiratory medications such as salbutamol, beclomethasone, and ipratropium for the management of chronic obstructive pulmonary disease (COPD) and asthma. Headquartered in Shanghai's Songjiang District, Harrison Pharmaceutical operates large-scale GMP-certified manufacturing facilities and serves both domestic and international markets through its specialized focus on inhalation formulation science.